SE453153B - Forfarande for beredning av en farmaceutisk, parenteral dosenhet av lyofiliserat natriumpiperacillin - Google Patents

Forfarande for beredning av en farmaceutisk, parenteral dosenhet av lyofiliserat natriumpiperacillin

Info

Publication number
SE453153B
SE453153B SE8200591A SE8200591A SE453153B SE 453153 B SE453153 B SE 453153B SE 8200591 A SE8200591 A SE 8200591A SE 8200591 A SE8200591 A SE 8200591A SE 453153 B SE453153 B SE 453153B
Authority
SE
Sweden
Prior art keywords
concentration
lyophilized
piperacillin
dosage unit
sodium piperacillin
Prior art date
Application number
SE8200591A
Other languages
English (en)
Swedish (sv)
Other versions
SE8200591L (sv
Inventor
B E Haeger
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22935482&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE453153(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of SE8200591L publication Critical patent/SE8200591L/
Publication of SE453153B publication Critical patent/SE453153B/sv

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • A61K31/43Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SE8200591A 1981-03-26 1982-02-02 Forfarande for beredning av en farmaceutisk, parenteral dosenhet av lyofiliserat natriumpiperacillin SE453153B (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24758681A 1981-03-26 1981-03-26

Publications (2)

Publication Number Publication Date
SE8200591L SE8200591L (sv) 1982-09-27
SE453153B true SE453153B (sv) 1988-01-18

Family

ID=22935482

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8200591A SE453153B (sv) 1981-03-26 1982-02-02 Forfarande for beredning av en farmaceutisk, parenteral dosenhet av lyofiliserat natriumpiperacillin

Country Status (23)

Country Link
JP (1) JPS57159708A (enrdf_load_html_response)
AT (1) AT395533B (enrdf_load_html_response)
AU (1) AU549784B2 (enrdf_load_html_response)
BE (1) BE892541A (enrdf_load_html_response)
CA (1) CA1209477A (enrdf_load_html_response)
CH (1) CH652306A5 (enrdf_load_html_response)
DE (2) DE3208505A1 (enrdf_load_html_response)
DK (1) DK157976C (enrdf_load_html_response)
ES (1) ES509234A0 (enrdf_load_html_response)
FR (1) FR2502624B1 (enrdf_load_html_response)
GB (1) GB2095551B (enrdf_load_html_response)
GR (1) GR78386B (enrdf_load_html_response)
HK (1) HK39189A (enrdf_load_html_response)
HU (1) HU186489B (enrdf_load_html_response)
IE (1) IE52936B1 (enrdf_load_html_response)
IL (1) IL64924A (enrdf_load_html_response)
IT (1) IT1147916B (enrdf_load_html_response)
LU (1) LU84031A1 (enrdf_load_html_response)
NL (1) NL192664C (enrdf_load_html_response)
NZ (1) NZ199632A (enrdf_load_html_response)
PL (1) PL130564B1 (enrdf_load_html_response)
SE (1) SE453153B (enrdf_load_html_response)
ZA (1) ZA82605B (enrdf_load_html_response)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207661B1 (en) 1999-02-22 2001-03-27 Baxter International Inc. Premixed formulation of piperacillin sodium and tazobactam sodium injection
CA2543242C (en) 2003-10-23 2015-04-14 Otsuka Pharmaceutical Co., Ltd. Controlled release sterile freeze-dried aripiprazole formulation and injectable formulation thereof
ITMI20051630A1 (it) * 2005-09-02 2007-03-03 Acs Dobfar Spa Formulazione farmaceutica sterile iniettabile contenente almeno due principi attivi
MY152789A (en) 2007-07-31 2014-11-28 Otsuka Pharma Co Ltd Methods for producing aripiprazole suspension and freeze-dried formulation
CN114200057A (zh) * 2021-12-14 2022-03-18 坛墨质检科技股份有限公司 一种可替代标准溶液的抗生素类药物固体混合标准物质的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2608507A (en) * 1949-08-20 1952-08-26 Sharp & Dohme Inc Dialkyl sulfamyl benzoic acids
CH546783A (de) * 1971-03-11 1974-03-15 Hoffmann La Roche Verfahren zur herstellung von penicilloinsaeurederivate.
JPS5817728B2 (ja) * 1973-11-20 1983-04-09 山之内製薬株式会社 アンピシリンナトリウムエン ノ セイホウ
IL47168A (en) * 1974-05-09 1979-07-25 Toyama Chemical Co Ltd Mono or dioxo piperazino(thio)carbonylamino derivatives ofpenicillins and cephalosporins and process for producing the same
JPS52143221A (en) * 1976-05-22 1977-11-29 Yamanouchi Pharmaceut Co Ltd Novel preparations for rectal administration
DE2623835C2 (de) * 1976-05-28 1978-03-02 C.H. Boehringer Sohn, 6507 Ingelheim Verfahren zur Herstellung von Natriumampicillin
JPS542337A (en) * 1977-06-08 1979-01-09 Toyama Chem Co Ltd Bactericidal composition for medical use
FR2403078A1 (fr) * 1977-09-19 1979-04-13 Lafon Labor Nouveau procede de preparation de formes pharmaceutiques, cosmetiques ou de diagnostic
JPS54147917A (en) * 1978-05-08 1979-11-19 Sumitomo Chem Co Ltd Ferrze-drying method
PT70225A (en) * 1978-10-03 1979-10-01 Gist Brocades Nv Process for the preparation of sodium amoxicillin preparations
DE2925009A1 (de) * 1979-06-21 1981-01-08 Basf Ag Zubereitung fuer substanzen, verfahren zu deren herstellung und deren verwendung

Also Published As

Publication number Publication date
PL235509A1 (enrdf_load_html_response) 1982-12-20
LU84031A1 (de) 1982-07-08
CH652306A5 (de) 1985-11-15
AU549784B2 (en) 1986-02-13
ATA92982A (de) 1992-06-15
IT1147916B (it) 1986-11-26
HU186489B (en) 1985-08-28
IE52936B1 (en) 1988-04-13
GB2095551B (en) 1984-10-03
FR2502624B1 (fr) 1985-10-25
DK48382A (da) 1982-09-27
GR78386B (enrdf_load_html_response) 1984-09-26
NL8201251A (nl) 1982-10-18
ES8302455A1 (es) 1982-12-16
DK157976B (da) 1990-03-12
GB2095551A (en) 1982-10-06
AU7986582A (en) 1982-09-30
CA1209477A (en) 1986-08-12
DE3208505A1 (de) 1982-10-21
ES509234A0 (es) 1982-12-16
DE19375106I2 (de) 2006-02-16
DK157976C (da) 1990-08-27
JPH0219804B2 (enrdf_load_html_response) 1990-05-07
JPS57159708A (en) 1982-10-01
DE3208505C2 (enrdf_load_html_response) 1991-11-28
ZA82605B (en) 1982-12-29
FR2502624A1 (fr) 1982-10-01
NL192664B (nl) 1997-08-01
IT8248034A0 (it) 1982-03-19
HK39189A (en) 1989-05-19
IL64924A0 (en) 1982-04-30
BE892541A (fr) 1982-09-20
SE8200591L (sv) 1982-09-27
AT395533B (de) 1993-01-25
IE820703L (en) 1982-09-26
NZ199632A (en) 1985-07-12
NL192664C (nl) 1997-12-02
PL130564B1 (en) 1984-08-31
IL64924A (en) 1985-07-31

Similar Documents

Publication Publication Date Title
CA2619255A1 (en) Twin-chamber receptacle without a bypass
BG61752B1 (bg) Аерозолни състави под налягане
US3914419A (en) Two compartment one unit consecutively injectable liquid vitamin package
DE2415101A1 (de) Pharmazeutische zusammensetzungen
CA2491685A1 (en) Liquid formulations with high concentration of human growth hormone (hgh) comprising 1,2-prolpylene glycol
DE60038118T2 (de) Formulierungen von wachstumshormonen
SE453153B (sv) Forfarande for beredning av en farmaceutisk, parenteral dosenhet av lyofiliserat natriumpiperacillin
DE60215129T3 (de) Esmolol-enthaltende zubereitungen
Miller et al. A comparative evaluation of compounding costs and contamination rates of intravenous admixture systems
US4534977A (en) Composition of matter comprising a low bulk density lyophilized preparation of Sodium Piperacillin
AU2005323389B2 (en) Container closure delivery system
US20150216928A1 (en) Daptomycin injectable formulation
CA1269205A (en) Adsorption-resistant peptide composition
US11701301B2 (en) Device, method and kit for the reconstitution of a solid or semi solid pharmaceutical composition
Allen Jr et al. Stability of labetalol hydrochloride, metoprolol tartrate, verapamil hydrochloride, and spironolactone with hydrochlorothiazide in extemporaneously compounded oral liquids
Wermeling et al. Osmolality of small-volume intravenous admixtures
EP0095751A1 (en) Secretin composition and method for preventing the adsorption of secretin
SE463804B (sv) En anvaendningsklar farmaceutisk komposition av vinkadimerasalter
EP0180303B1 (en) Parenteral composition
JP2000500994A (ja) 水性アシクロビル製剤とその貯蔵方法
Benabbes et al. 3PC-044 Paraffin oil-based emulsion: influence of gum arabic and the mixing rate on emulsion stability
JPS5977862A (ja) 医療用容器
US20150174248A1 (en) Injectable antibiotic formulations and their methods of use
KR860000512B1 (ko) 페니실린 유도체의 동결 건조물로 된 주사용량 단위물 제조방법
Weaver In vitro Adsorption of Sodium Pentobarbitol by Superchar, USP and Darco G-60 Activated Charcoals

Legal Events

Date Code Title Description
NAL Patent in force

Ref document number: 8200591-9

Format of ref document f/p: F

NUG Patent has lapsed

Ref document number: 8200591-9

Format of ref document f/p: F